Cessatech AS (XSAT:CESSA) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CESSA Cessatech AS XSAT:CESSA
28 GF Score
Price kr10.40
! 2 Warning Signs
View Full Analysis

What is Cessatech AS Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XSAT:CESSA
28GF Score
Cessatech AS XSAT:CESSA
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cessatech AS Business Description

Other Exchanges 8GN:Germany
Address Strandvejen 60, Hellerup, DNK, DK- 2900
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
28GF Score

Get the complete analysis for XSAT:CESSA

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.40
Price